Roche Licenses Halozyme's ENHANZE Technology for ~$190M for the Development of Therapeutic Targets
Shots:
- Halozyme to receive $25M upfront plus $160 to $165M/target milestones payments based on development- regulatory & sales in addition to royalties. Roche to get rights for ENHANZE Technology for exclusive development of clinical stage candidates for therapy areas
- Roche also has an option to add two additional targets within a span of four years- in response Halozyme will receive a nomination fee for added targets. The initiation of the transaction is expected in Q4’19
- Halozyme’s ENHANZE drug discovery technology is based on recombinant human hyaluronidase enzyme (rHuPH20) with SC delivery system. In 2006- Roche & Halozyme signed an agreement for ENHANZE and developed Rituxan- Rituxan Hycela & Herceptin
Ref: Halozyme | Image: Roche
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com